Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Moderna, Inc.

Market Cap 18.94B 16.38B 15.1B 14.15B 26.42B 1,806B 26.91B 179B 69.49B 873B 71.11B 69.57B 3,035B P/E ratio 2026 *
-5.52x
P/E ratio 2027 * -10.1x
Enterprise value 15.38B 13.3B 12.26B 11.49B 21.46B 1,467B 21.85B 145B 56.43B 709B 57.75B 56.49B 2,465B EV / Sales 2026 *
7.37x
EV / Sales 2027 * 6.63x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -
1 day+0.27%
1 week+4.58%
Current month+1.14%
1 month-12.18%
3 months-14.37%
6 months+69.02%
Current year+61.85%
1 week 45.4
Extreme 45.4
51.9
1 month 43.9
Extreme 43.9
59.48
Current year 29.81
Extreme 29.81
59.55
1 year 22.28
Extreme 22.28
59.55
3 years 22.28
Extreme 22.28
170.47
5 years 22.28
Extreme 22.28
497.49
10 years 11.54
Extreme 11.54
497.49
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2011
Director of Finance/CFO 49 06/09/2022
President 50 01/11/2024
Director TitleAgeSince
Chairman 62 01/02/2012
Director/Board Member 54 01/03/2011
Director/Board Member 69 11/12/2019
Date Insider Type Main position Quantity % Market Cap.
01/06Fiscal year

General Counsel

5,377 0.0014%
01/06Fiscal year

Chairperson

23,052 0.0058%
01/06Fiscal year

Chief Financial Officer

6,147 0.0015%
Change 5-day change 1-year change 3-year change Capi.($)
+0.27%+4.58%+69.62%-61.28% 18.89B
+0.79%+2.20%+19.05%-17.46% 62.2B
+0.50%+5.64%+63.43%+206.21% 57.37B
+4.26%+29.60%+29.60%+29.60% 36.99B
+2.88%+10.72%-58.17%-66.90% 33.6B
+3.36%+5.44%+48.42%-35.54% 28.44B
+2.57%+11.91%+47.70%+69.12% 20.11B
-1.85%+0.18%+41.95%+96.84% 16.26B
-0.27%-5.53%-10.48%+102.23% 16.25B
+0.46%+5.95%+73.41%+323.00% 13.2B
Average +1.23%+1.52%+32.45%+64.58% 30.33B
Weighted average by Cap. +1.45%+1.93%+29.99%+53.78%

Financials

2026 *2027 *
Net sales 2.09B 1.81B 1.66B 1.56B 2.91B 199B 2.97B 19.73B 7.66B 96.26B 7.84B 7.67B 334B 2.51B 2.17B 2B 1.88B 3.51B 240B 3.57B 23.75B 9.22B 116B 9.43B 9.23B 403B
Net income -3.4B -2.94B -2.71B -2.54B -4.75B -325B -4.84B -32.18B -12.49B -157B -12.78B -12.5B -546B -1.84B -1.59B -1.47B -1.37B -2.57B -175B -2.61B -17.4B -6.75B -84.86B -6.91B -6.76B -295B
Net Debt -3.56B -3.08B -2.84B -2.66B -4.97B -339B -5.06B -33.65B -13.06B -164B -13.37B -13.08B -570B -2.27B -1.97B -1.81B -1.7B -3.17B -217B -3.23B -21.49B -8.34B -105B -8.54B -8.35B -364B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Date Price Change Volume
09/06/26 47.73 $ +0.27% 5,079,123
08/06/26 47.60 $ +0.34% 3,994,555
05/06/26 47.44 $ -8.04% 6,084,113
04/06/26 51.59 $ +5.16% 6,709,675
03/06/26 49.06 $ +7.49% 6,934,371
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
24
Last Close Price
47.73USD
Average target price
43.30USD
Spread / Average Target
-9.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MRNA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW